4D Molecular Therapeutics Inc expected to post a loss of 90 cents a share - Earnings Preview

4D Molecular Therapeutics

08/05/2023 14:00

* 4D Molecular Therapeutics Inc  FDMT.OQ   FDMT.O  is
expected
to show a fall in quarterly revenue when it reports  results on
May 10 (estimated). 
    * The Emeryville California-based  company is expected to
report 
a 15.7% decrease in revenue to $1.028 million from $1.22 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for 4D Molecular
Therapeutics
Inc is for a loss of 90 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for 4D
Molecular
Therapeutics Inc is $36​, above​ its last closing price
of $16.94. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.83       -0.79      -0.84     Missed  -6.9
 Sep. 30 2022  -0.88       -0.91      -0.79     Beat    13.4
 Jun. 30 2022  -0.87       -0.85      -0.87     Missed  -2.4​
 Mar. 31 2022  -0.78       -0.81      -0.82     Missed  -1.2
 ​​Dec.        -0.85       -0.86      -0.85     Beat    1.2
 31 2021                                                
 Sep. 30 2021  -0.83       -0.80      -0.82     Missed  -1.9​
 Jun. 30 2021  -0.68       -0.68      -0.28     Beat    58.8
 Mar. 31 2021  -1.10       -1.10      -0.61     Beat    44.5
 This summary was machine generated May 8 at 13:00 GMT.  All
figures in US dollars  unless otherwise stated